December 8, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay

December 8, 2020 at 10:17 AM EST CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. The... Read more

December 3, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

December 3, 2020 at 10:00 AM EST CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecular tests with ambient temperature stability. This specialized master mix is designed... Read more